Chemical compounds

1 . A compound of formula (I):

wherein:

n and m are, independently, 0 or 1;

A, B, D, E, G represent one each of CCO 2 R 5 , CR 2 , CR 3 , CR 4 , and CH or N,

Q is hydrogen or hydroxy;

W is CH 2 , O, NH or N(C 1-4 alkyl);

R 1 is phenyl optionally substituted by halogen, cyano, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy;

R 2 , R 3 and R 4 are, independently, hydrogen, halogen, cyano, nitro, hydroxy, NR 6 R 7 , C 1-6 alkyl (optionally substituted with halogen), C 1-6 alkoxy (optionally substituted with halogen), S(O) p (C 1-6 alkyl), S(O) q CF 3 or S(O) 2 NR 7 R 8 ;

R 5 is hydrogen, C 1-6 alkyl or benzyl;

p and q are, independently, 0, 1 or 2;

R 6 , R 7 , R 8 and R 9 are, independently, hydrogen, C 1-6 alkyl (optionally substituted by halogen, hydroxy or C 3-6 cycloalkyl), CH 2 (C 2-5 alkenyl), phenyl (itself optionally substituted by halogen, hydroxy, nitro, NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 (and these alkyl groups may join to form a ring as described for R 6 and R 7 below), S(O) 2 (C 1-4 alkyl), S(O) 2 NH 2 , S(O) 2 NH(C 1-4 alkyl), S(O) 2 N(C 1-4 alkyl) 2 (and these alkyl groups may join to form a ring as described for R 6 and R 7 below), cyano, C 1-4 alkyl, C 1-4 alkoxy, C(O)NH 2 , C(O)NH(C 1-4 alkyl), C(O)N(C 1-4 alkyl) 2 (and these alkyl groups may join to form a ring as described for R 6 and R 7 below), CO 2 H, CO 2 (C 1-4 alkyl), NHC(O)(C 1-4 alkyl), NHS(O) 2 (C 1-4 alkyl), C(O)(C 1-4 alkyl), CF 3 or OCF 3 ) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 (and these alkyl groups may join to form a ring as described for R 6 and R 7 below), S(O) 2 (C 1-4 alkyl), S(O) 2 NH 2 , S(O) 2 NH(C 1-4 alkyl), S(O) 2 N(C 1-4 alkyl) 2 (and these alkyl groups may join to form a ring as described for R 6 and R 7 below), cyano, C 1-4 alkyl, C 1-4 alkoxy, C(O)NH 2 , C(O)NH(C 1-4 alkyl), C(O)N(C 1-4 alkyl) 2 (and these alkyl groups may join to form a ring as described for R 6 and R 7 below), CO 2 H, CO 2 (C 1-4 alkyl), NHC(O)(C 1-4 alkyl), NHS(O) 2 (C 1-4 alkyl), C(O)(C 1-4 alkyl), CF 3 or OCF 3 );

alternatively NR 6 R 7 or NR 8 R 9 may, independently, form a 4-7 membered heterocyclic ring,

or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

2 . A compound of formula (I) as claimed in claim 1 wherein W is O.

3 . A compound as claimed in claim 1 wherein n and m are both 1.

4 . A compound as claimed in claim 1 , wherein R 1 is phenyl optionally substituted with halogen, cyano, C 1-4 alkyl or C 1-4 alkoxy.

5 . A compound of formula (I) as claimed in claim 1 wherein Q is hydrogen.

6 . A compound of formula (I) as claimed in claim 1 wherein one of A, B, D, E, G represent one each of CCO 2 R 5 , CR 2 , CR 3 , CR 4 , and CH or N; wherein R 2 , R 3 and R 4 , are, independently, hydrogen, halogen, cyano, nitro, C 1-4 alkyl, C 1-4 alkoxy, CF 3 , OCF 3 , S(O) 2 (C 1-4 alkyl) or S(O) 2 NH 2 ; and R 5 is hydrogen or C 1-6 alkyl.

7 . A process for preparing a first compound of formula (I) as claimed in claim 1 , the process comprising:

a. nucleophilic substitution of fluoride (II):

with a compound of formula (III):

in the presence of a suitable solvent, at a suitable temperature, optionally in the presence of a suitable base;

b. when R 5 is hydrogen, said first compound may be converted to a second compound of formula (I) as claimed in claim 1 where R 5 is not hydrogen by a standard esterification method well known in the art;

c. when R 5 is not hydrogen said compound may be converted to a second compound of formula (I) as claimed in claim 1 where R 5 is hydrogen by a standard ester hydrolysis method well known in the art; or

d. a Buchwald-Hartwig amination, where a compound of formula (VIII):

wherein L 1 is bromo or iodo; is reacted with a compound of formula (III):

in the presence of a suitable palladium compound, a ligand, a base and a solvent, at a suitable temperature.

8 . A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1 , and a pharmaceutically acceptable adjuvant, diluent or carrier.

9 - 10 . (canceled)

11 . A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1 .

12 . The compound as claimed in claim 1 , wherein NR 6 R 7 or NR 8 R 9 , independently, form azetidine, pyrrolidine, piperidine, azepine, morpholine or piperazine, each of which is optionally substituted by C 1-4 alkyl on the distal nitrogen.

13 . A compound as claimed in claim 2 , wherein n and m are both 1.

14 . A compound as claimed in claim 2 , wherein R 1 is phenyl optionally substituted with halogen, cyano, C 1-4 alkyl or C 1-4 alkoxy.

15 . A compound as claimed in claim 2 , wherein Q is hydrogen.

16 . A compound as claimed in claim 12 , wherein W is 0.

17 . A compound as claimed in claim 12 , wherein one of A, B, D, E, G represent one each of CCO 2 R 5 , CR 2 , CR 3 , CR 4 , and CH or N; wherein R 2 , R 3 and R 4 , are, independently, hydrogen, halogen, cyano, nitro, C 1-4 alkyl, C 1-4 alkoxy, CF 3 , OCF 3 , S(O) 2 (C 1-4 alkyl) or S(O) 2 NH 2 ; and R 5 is hydrogen or C 1-6 alkyl.

18 . A compound as claimed in claim 12 , wherein n and m are both 1.

19 . A compound as claimed in claim 12 , wherein R 1 is phenyl optionally substituted with halogen, cyano, C 1-4 alkyl or C 1-4 alkoxy.

20 . A compound as claimed in claim 12 , wherein Q is hydrogen.

21 . A compound as claimed in claim 12 , wherein one of A, B, D, E, G represent one each of CCO 2 R 5 , CR 2 , CR 3 , CR 4 , and CH or N; wherein R 2 , R 3 and R 4 , are, independently, hydrogen, halogen, cyano, nitro, C 1-4 alkyl, C 1-4 alkoxy, CF 3 , OCF 3 , S(O) 2 (C 1-4 alkyl) or S(O) 2 NH 2 ; and R 5 is hydrogen or C 1-6 alkyl.